Rhumbline Advisers Decreases Stake in Bristol Myers Squibb Company $BMY

Rhumbline Advisers lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 3.4% in the third quarter, HoldingsChannel.com reports. The firm owned 3,664,767 shares of the biopharmaceutical company’s stock after selling 128,722 shares during the quarter. Rhumbline Advisers’ holdings in Bristol Myers Squibb were worth $165,281,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Harbor Capital Advisors Inc. increased its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. Total Investment Management Inc. acquired a new position in Bristol Myers Squibb during the second quarter worth $38,000. Twin Peaks Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb during the second quarter worth $40,000. Finally, Mark Sheptoff Financial Planning LLC increased its position in shares of Bristol Myers Squibb by 233.3% in the second quarter. Mark Sheptoff Financial Planning LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

BMY opened at $59.91 on Thursday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The company’s 50 day simple moving average is $55.00 and its 200 day simple moving average is $49.28. The stock has a market capitalization of $121.96 billion, a PE ratio of 17.37, a P/E/G ratio of 0.17 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 70.30% and a net margin of 14.64%.The company’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same period last year, the business posted $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $66.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Wednesday, January 28th. Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a research report on Wednesday, December 3rd. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. The Goldman Sachs Group reissued a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Finally, Citigroup upped their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Eight investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $59.20.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.